Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy

The T‐cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T‐cell therapy.

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Case Rep
Main Authors: Tambaro, Francesco Paolo, Khazal, Sajad, Nunez, Cesar, Ragoonanan, Dristhi, Tewari, Priti, Petropoulos, Demetrios, Kebriaei, Partow, Wierda, William George, Mahadeo, Kris Michael
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Case Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7495807/
https://ncbi.nlm.nih.gov/pubmed/32983475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.2918
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados